Status:
UNKNOWN
Efficacy and Safety of Endoscopic Ultrasound Guided Fine-needle Injection of Dendritic Cells Vaccination Into Unresectable Pancreatic Cancer
Lead Sponsor:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Pancreatic cancer is the second most frequent gastrointestinal malignancy. The overall survival is dismal. Especially for advanced pancreatic cancer, the conventional approaches are typically not cura...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed adenocarcinoma of the pancreas.
- Patients must be deemed unresectable due to involvement of important vasculature, adjacent organ invasion, presence of metastasis, or other medical condition making surgical resection unfavorable.
- Life expectancy of \>3 months.
- Karnofsky performance status \>50%.
- Patients must have adequate clotting and coagulation function (platelet \> 100k; INR\<1.4).
- Able and willing to sign a written informed consent.
Exclusion
- Patients receiving anticoagulation therapy.
- Steroids or immunosuppressing agent dependant status
- Patients who have received prior gemcitabine or radiation therapy in the past 4 weeks
- Ongoing infection
- Pregnancy or breast-feeder
- Other concurrent diseases including other malignancy,psychiatric illness,heart, lung and renal disfunctions
- Massive ascites
- Decision of unsuitableness by principal investigator or physician-in-charge
Key Trial Info
Start Date :
December 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2017
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01897636
Start Date
December 1 2013
End Date
March 1 2017
Last Update
July 12 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanjing Drum-Tower Hospital
Nanjing, Jiangsu, China, 210008